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SUMMARY
Information on the period during which infants lose their
maternally derived antibodies to malaria and begin to
acquire naturally their own immune responses against para-
site antigens is crucial for understanding when malaria vac-
cines may be best administered. This study investigated the
rates of decline and acquisition of serum antibody isotypes
IgG1, IgG2, IgG3, IgG4, IgM and IgA to Plasmodium fal-
ciparum antigens apical membrane antigen (AMA1), mero-
zoite surface proteins (MSP1-19, MSP2 and MSP3) in a
birth cohort of 53 children living in an urban area in the
Gambia, followed over the first 3 years of life (sampled at
birth, 4, 9, 18 and 36 months). Antigen-specific maternally
transferred antibody isotypes of all IgG subclasses were
detected at birth and were almost totally depleted by
4 months of age. Acquisition of specific antibody isotypes to
the antigens began with IgM, followed by IgG1 and IgA.
Against the MSP2 antigen, IgG1 but not IgG3 responses
were observed in the children, in contrast with the mater-
nally derived antibodies to this antigen that were mostly
IgG3. This confirms that IgG subclass responses to MSP2
are strongly dependent on age or previous malaria experi-
ence, polarized towards IgG1 early in life and to IgG3 in
older exposed individuals.
Keywords acquired immunity, antibody isotypes, birth
cohort, blood stage antigens, Plasmodium falciparum
INTRODUCTION
Infants are protected from a number of infections by
maternally transferred immunity. This immunity is not
long-lasting, and children need to acquire immunity
against common pathogens early in life. For malaria, a
degree of resistance in endemic areas in the first 3–
6 months of age has been attributed to a combination of
protection by maternally transferred antibodies, foetal hae-
moglobin that cannot support parasite development, lack
of p-aminobenzoic acid (PABA) in the infant breast milk
diet which prevents parasite growth and limited exposure
to vectors (1–7).
However, it has not been straightforward to demon-
strate an association between maternal antibodies and pro-
tection of infants from malaria infection. A study
conducted in Ghana showed that infants with high levels
of maternal antibodies to Plasmodium falciparum antigens
were found to be more susceptible to malarial attack, sug-
gesting that maternally derived antibodies are an epidemi-
ological marker for risk of infection in infants (2). A study
in Tanzania also indicated that IgG antibodies to circums-
porozoite protein (CSP) and merozoite surface protein 1
(MSP1) in infants were not protective against parasitaemia
(8). Findings from a study of Nigerian infants also showed
no association between levels of maternally derived anti-
bodies reactive with parasite schizont extract and the age
of first clinical episode of malaria (9). However, a study in
Kenya showed that high levels of antibodies detected in
maternal sera were associated with a longer time to first
clinical malaria episode (10). From the varying results of
these studies, the role of maternal antibodies in the protec-
tion of infants is unclear.
Positive serum IgG levels to several different P. falcipa-
rum blood stage antigens, such as merozoite surface pro-
teins (MSP1-19, MSP1 block 2, MSP2), apical membrane
antigen (AMA1) and erythrocyte binding antigen
(EBA175), have been shown to be associated with reduced
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where the subclass has been investigated, it is cytophilic
and complement fixing IgG1 and IgG3 subclasses that are
most strongly associated with protection (11–31). However,
the IgG protective association was not seen with some of
the antigens, such as MSP1-19 in Ghana, and also ring-
infected erythrocyte surface antigen (RESA) and MSP1 in
Papua New Guinea and Madagascar (17,32). IgG sub-
classes IgG2 and IgG4 have been found to lack the ability
to activate cytotoxic cells and have been linked to the
blocking of protective mechanisms (33). As the effect of
antibodies is enhanced by their ability to bind Fc recep-
tors on phagocytic cells, this can explain why IgG2 and
IgG4 are not able to trigger phagocytosis, because the for-
mer binds to the FcRIIA-H131 (an allele of the Fc recep-
tor that is not associated with protection) and the latter
does not bind to FcRIIA at all. However, high IgG2 and
low IgG4 levels have been associated with human resis-
tance to P. falciparum malaria in Burkina Faso, where
high level of IgG2 to RESA and merozoite surface protein
2 (MSP2) inversely correlated with risk of infection and
vice versa for IgG4 (20). Similarly, in Cameroon high levels
of IgG2 were associated with reduced risk of P. falciparum
infection in infants from birth to 6 months of age (34).
An in vitro study showed that IgG4 hinders IgG1- and
IgG3-mediated opsonization of infected erythrocytes (35).
There is thus some lack of consistent findings among pro-
tective association studies, which may be a result of para-
site and host genetic variation as well as the design of the
studies. Subclass specificities to blood stage antigens have
been shown to display a level of age dependency. The pre-
dominant subclass for MSP1-19 antigen is IgG1 in all age
groups, with the levels of both IgG1 and IgG3 increasing
with age. For MSP2, there is age-related change from
IgG1 to IgG3, whereas for AMA1, IgG1 is the predomi-
nant antibody and for MSP3, the predominant antibodies
are IgG1 and IgG3 in all age groups (11,17,27,36–38).
The evidence indicating an association between age and
the predominance of IgG1 and IgG3 responses to the P. fal-
ciparum MSP2 in endemic populations is quite strong. A
study conducted in Tanzania with subjects from villages
located at different altitudes (malaria transmission dimin-
ishes with altitude) demonstrated the effect of antigen, age
and exposure on IgG subclass responses (39). The IgG1
subclass to AMA1 and MSP1-19 was predominant in sera
from all age groups. However, IgG3 responses to MSP2
antigen were more age-dependent, with a predominance of
IgG1 in younger children and of IgG3 in older children and
adults. The IgG3 levels to MSP2 became more apparent
after 2 years of age, and were higher than IgG1 by 15 years
of age. This confirmed an earlier finding in the Gambia,
where it was shown that IgG1 responses predominated in
children but IgG3 to MSP2 antigens predominated in
adults (11). Interestingly, a recent study on nonimmune
travellers returning to France with P. falciparum malaria
showed that their antibodies against MSP2 were not of the
IgG3 subclass but were almost exclusively IgG1 (40).
Therefore, it was hypothesized that differences exist in the
rate of acquisition of different antibody isotypes or sub-
classes to blood stage malaria antigens, or that there are
different determinants for these responses.
For the detection of differences in the rate of acquisition
of antibodies to blood stage antigens, a birth cohort study is
ideal. This study design involves the follow-up of infants
over time as they may be exposed to natural infections, and
allows for the estimation of the rate of acquisition of anti-
body isotypes over time in the individuals. Several vaccines
that are under development are ultimately intended to prime
responses to these antigens in infants, so naturally acquired
responses need to be described adequately. This study inves-
tigated the rate of decline of maternally derived antibodies,
and the acquisition of antibodies to P. falciparum blood
stage antigens in a Gambian birth cohort, in an attempt to
test for differences in the rates of decline and natural acqui-
sition of antibody isotypes to blood stage antigens.
MATERIALS AND METHODS
Study site and population
This study was performed in The Gambia where malaria
transmission is highly seasonal, and most infections occur
annually between August and November, during and imme-
diately following the single rainy season from June to Octo-
ber (41). A cohort of 134 children recruited at birth (July
2003–February 2004) from the Sukuta Health Centre mater-
nity ward was initially sampled to investigate antibody
responses to alternative schedules of measles vaccination.
The Health Centre serves an urban⁄peri-urban population
that is part of the Greater Banjul Area in the coastal part of
The Gambia. Infants from this area are mostly breast-fed
into their second year of life. The recruitment criterion for
the cohort was that births should be singletons with no
congenital abnormalities, but with a birth weight of over
1Æ8 kg. The HIV status of the study subjects was unknown,
but adult HIV prevalence in the region was below 2Æ5% at
the time of the study (National AIDS Control Programme,
unpublished data); therefore it was unlikely to be a
significant confounder. All the subjects received childhood
vaccinations as part of the Expanded Programme of Immu-
nization (EPI) schedule, but were randomized to receive an
extra dose of measles vaccine and were followed up from
birth for the acquisition of immune responses. The children
had access to the Health Centre, where a resident nurse was
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study period.
Cord blood samples and then blood samples at 4, 9, 18
and 36 months of age were collected, and the plasma
stored at )20 C until antibody assays were performed. Of
the 134 children recruited for the study on responses to
measles vaccine, 53 had samples for all five time points up
to the age of 36 months, and were therefore selected for
the current investigation on naturally acquired antibodies
to malaria antigens. Good data on post-natal episodes of
malaria were not available because it was not part of the
study design to capture these, and malaria is commonly
treated presumptively in the community.
P. falciparum blood stage antigens
In this study, the antigens employed in assays were Escher-
ichia coli expressed recombinant proteins, as follows. The
recombinant AMA1 is the full-length ectodomain repre-
senting amino acids 83–531 of AMA1 in the 3D7 clone
(42). The 19-kDa fragment of MSP1-19 is a glutathione
s-transferase (GST) fusion protein representing amino acids
1631–1726 of MSP1 in the Wellcome isolate (43). Two
MSP2 allelic antigens are GST fusion proteins of MSP2
amino acid sequences 1–184 of the ch150⁄9 isolate and
22–247 of the Dd2 clone (44,45); Two MSP3 allelic anti-
gens are maltose-binding protein (MBP) fusion proteins
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Figure 1 The mean OD and SE of cord
blood plasma antibody isotype reactivities
to antigens for children in each birth
month (July, n = 5; August, n = 15; Sep-
tember, n = 17; January, n = 7; February,
n = 9). Serum dilutions used for the
detection of IgG subclasses are indicated
in brackets in the graph (1⁄500 for IgG1
and IgG3, 1⁄50 for IgG2 and IgG4).
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354 of the 3D7 clone and 2–379 of the K1 isolate (37).
Recombinant proteins representing the GST and MBP
fusion tags were also assayed as controls.
Antibody assays
Enzyme-linked immunosorbent assays were used to detect
the reactivity of antibody isotypes IgG1, IgG2, IgG3,
IgG4, IgM and IgA in plasma to a panel of blood stage
antigens AMA1, MSP1-19, MSP2-ch150⁄9, MSP2-Dd2,
MSP3-3D7 and MSP3-K1. Briefly, wells of flat bottom
96-well plates (Immulon 4HBX, ThermoLabs, Waltham,
MA, USA) were coated with 50 ng of recombinant anti-
gen (all antigens) in 100 lL of coating buffer (15 mM
Na2CO3,3 5m M NaHCO3,p H9 Æ3). The plates were incu-
bated at 4 C overnight and then washed four times with
PBS-T (PBS with 0Æ05% v⁄v Tween 20). Unoccupied pro-
tein binding sites on the plate were blocked with 200 lL
per well of blocking buffer (1% skimmed milk, Marvel
TM
UK, in PBS-T) for 5 h at room temperature. Plates were
washed prior to the addition of 100 lL of each plasma
diluted with blocking buffer (1⁄500 for IgG1 and IgG3;
1⁄50 for IgG2, IgG4, IgM and IgA), dilutions chosen
after optimization of assays for each isotype. After incuba-
tion at 4 C overnight, the plates were washed four times
and 100 lL of horseradish peroxidase (HRP) conjugated
sheep antibodies specific to detect each of the human IgG
subclasses (The Binding Site, UK; anti-IgG1-4 reagents
AP006-AP009), and HRP conjugated rabbit anti-human
IgM or IgA (Dako, UK; reagents P0215 and P0216
respectively) at 1⁄5000 were added to each well and incu-
bated at room temperature for 3 h. Plates were washed
four times and antibody reactivities detected with 100 lL
of substrate (0Æ4m g⁄mL of o-phenylenediamine; 0Æ08%
v⁄vH 2O2) in developing buffer (24Æ5m M citric acid mono-
hydrate; 52 mM Na2HPO4,p H5 Æ0). The reaction was
stopped with 50 lLo f2 M H2SO4 and optical density
(OD) of plates measured at 490 nm. The assays were run
in duplicate wells with different time point samples from
each individual run on the same plate. The OD reading
was corrected for nonspecific binding by subtracting the
OD for antibody reactivity to the relevant fusion tags,
MBP for MSP3 recombinant proteins and GST for MSP1
and MSP2 recombinant proteins. Antibody isotype reac-
tivities of 20 nonimmune negative control individuals
(European tourists in The Gambia) were also assayed.
Data analysis
Data generated from assays in the form of ELISA OD val-
ues were entered into Microsoft Excel worksheets and then
transferred to SPSS version 11 (SPSS Inc., Chicago, IL,
USA) and GraphPad Prism version 4Æ0 (GraphPad Soft-
ware, San Diego, CA, USA) for analysis. An antibody
isotype level was considered positive if the individual’s
OD reading was above a cut-off value (mean + 3 standard
deviation of values from the panel of 20 nonimmune con-
trol sera). Statistical comparisons of antibody isotype lev-
els in cord blood among different calendar birth months
were performed using Wilcoxon’s signed rank test.
RESULTS
Effect of month of birth on antibody isotype levels in
cord blood sera
Of the 53 children analysed with all time point samples in
the cohort, 5 (10%) were born in July 2003, 15 (28%) in
August 2003, 17 (32%) in September 2003, 7 (13%) in Jan-
uary 2004 and 9 (17%) in February 2004. The mean levels
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Figure 2 Proportion of children with positive reactivities of anti-
body isotypes IgG1, IgG2, IgG3, IgG4, IgM and IgA to antigens
at ages 0, 4, 9, 18 and 36 months. Each line represents the change
in proportions of children with positive reactivities (ELISA OD
>mean + 3 SD of negative control sera panel) against specific
antigens at different ages.
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birth month are shown in Figure 1. There were differences
in the levels of IgG1 and IgG3 to most antigens between
the birth months, with levels generally increasing after July
2003. Considering the profile of reactivities to the panel of
six antigens for each isotype, comparisons were made
between levels in the cord blood in different birth months.
Testing all pairwise comparisons separately, there were sig-
nificantly lower IgG1 levels in cord blood of births in July
2003 than that in August 2003 (P =0 Æ04) or January 2004
(P =0 Æ02). For IgG3, levels were significantly lower in
July 2003 than in August 2003 (P =0 Æ005), September
2003 (P =0 Æ006) or January 2004 (P =0 Æ02), and levels
were also lower in August 2003 than in January 2004
(P =0 Æ04). Levels of IgG2 were very low generally,
although even lower in September 2003 than in January
2004 (P =0 Æ01). For IgG4, there were no differences in
levels between the birth months. Most of these differences
were not significant after a Bonferroni correction for mul-
tiple comparisons, except for IgG3 levels that were signifi-
cantly lower in July 2003 (prior to the malaria season)
than that in other months.
Proportion of children with positive antibody reactivities
to blood stage antigens in cord blood
The relative levels of different antibody isotypes in cord
blood sera were observed to vary among antigens (Fig-
ure 1). Prevalence of IgG1 positivity was highest for
AMA1 (94%), followed by MSP3-3D7 and MSP3-K1
(66% each), MSP1-19 (62%), MSP2-Dd2 (28%) and
MSP2-ch150⁄9 (25%). In contrast, IgG3 positivity was
highest to MSP2-Dd2 and MSP2-ch150⁄9 (85% and 83%
respectively), followed by MSP3-K1 and MSP3-3D7 (53%
and 43% respectively), AMA1 (32%) and MSP1-19 (26%).
For IgG2 and IgG4, proportions positive were highest to
MSP2-ch150⁄9 (53% and 45% respectively). No positive
reactivities were observed for IgM and IgA to any of the
antigens in the cord sera, consistent with the suggestion
that these two isotypes are not transferred through the
placenta to infants by mothers.
Decline of antibody isotype responses to blood stage
antigens
Antibody isotype reactivities to malaria antigens were
analysed for samples collected at follow-up ages 4, 8 or 9,
18 and 36 months. A decline of all the IgG subclasses to
all antigens was first observed in the children at 4 months
of age. Detectable IgG1 to AMA1 persisted for longer
because of high initial levels, as demonstrated by the pro-
portion of children with positive levels at 4 months of age
(Figure 2). After 9 months, most antibody levels were
undetectable, except IgG1 to AMA1 in a minority of indi-
viduals.
Acquisition of antibody isotypes
The primary antibody isotype IgM to AMA1 was detected
in some children, with positive responses increasing with
age, although only in a minority of individuals, 6% at
4 months, 15% at 18 months and 23% at 36 months (Fig-
ure 2). To each of the antigens, IgA was detected in a
small minority, increasing after 9 months of age. Acquisi-
tion of IgG1 to AMA1, MSP1-19 and MSP2 occurred in
a few individuals from 4 or 9 months onwards, and to
MSP3 from 18 months of age. IgG1 to MSP1-19 was
acquired by 9% of the children from 18 to 36 months. For
the MSP2 allelic antigens, IgG1 to MSP2-ch150⁄9 was
acquired by 4% of the children at 18 months, while 8%
and 15% of the children were positive for responses
against MSP2-Dd2 at 9 and 18 months respectively. IgG1
response against MSP3-K1 was also found in 4% and 8%
of the children at 18 and 36 months, respectively. Fig-
ures 3, 4, 5a, b shows the decline and acquisition of the
antibody isotypes IgG1, IgG2, IgG3, IgG4, IgM and IgA
to AMA1, MSP1-19, MSP3-3D7 and MSP3-K1, respec-
tively.
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Figure 3 The decline and acquisition of the antibody isotypes,
IgG1, IgG2, IgG3, IgG4, IgM and IgA, to AMA1 over the five
time points 0, 4, 9, 18 and 36 months. Each line represents the
measurement of antibody levels in an individual at different ages.
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in the cord blood was dominated by IgG3. In contrast,
acquisition of IgG1 to MSP2 occurred in individual chil-
dren (Figure 6a, b), whereas there was no observation of
an IgG3 response to MSP2 in any of the children.
DISCUSSION
Maternally transferred antibody reactivities in cord blood
to the panel of antigens followed the polarized pattern of
IgG1 to AMA1 and MSP1-19, and IgG3 for MSP2-
ch150⁄9 and MSP2-Dd2, previously described for endemic
sera in The Gambia and elsewhere (11,39,44,45). A more
equal distribution of both IgG1 and IgG3 isotypes against
MSP3 was observed, as reported previously (37,46). The
decline of maternally derived IgG subclass antibodies
occurred as expected, so that by 4 months, most of the
antibodies were depleted.
The birth month of the children was associated with dif-
ferences in the level of antibodies detected in the cord
plasma. The Gambia experiences annual rainfall from
June to October and thus seasonal malaria transmission
occurs at this period, with a peak of incidence between
August and November (41,47). Therefore, it was not sur-
prising to observe relatively low antibody isotype levels in
the cord plasma from children born in July. Significantly
higher levels of antibody isotypes to the antigens were
seen in children born from August 2003 to February 2004,
implying a boost of antibody responses in some of the
mothers because of exposure to malaria parasites during
the transmission season. Antibodies previously acquired
would to some extent be depleted during the dry season as
a result of lack of boosting by re-infection (48), and conse-
quently lower levels of antibodies would be transferred by
mothers in July (2,9,10).
It is important to note that although antibodies to
MSP2 are predominantly IgG3 in the cord blood, children
who made a response produced IgG1 against MSP2. This
shows that IgG1 is the first IgG subclass synthesized
against this malaria antigen after primary infections. This
is consistent with the previous suggestion that there is an
exposure-related shift from IgG1 to IgG3 to MSP2 anti-
gens (11,49). It also implies that IgG3 is produced in the
later years, probably in response to subsequent infections.
As isotype subclass switching cannot occur in B-cell lines
from IgG1 to IgG3, the IgG3 response to MSP2 antigen
in latter years or subsequent infections will rely on the for-
mation of new B cells with an IgM switch to IgG3. Adults
living in malaria endemic areas have high levels of cyto-
philic antibodies IgG1 and IgG3 to malaria antigens and
these may be protective. It is possible that the IgG1
responses in young children (rather than IgG3) may not
be protective, but that IgG3 responses that are acquired
later are more protective (31).
An increase of antibody levels in these children was
expected with age. However, it was observed that the pro-
portions with any antibody responses from 9 months of
age onwards were very low. A recent decline in the inci-
dence of malaria in The Gambia, particularly since 2003
(41), accounts for a low level of exposure in this cohort. A
majority of the children sleep under insecticide-treated bed
nets and are therefore protected from infectious bites at
night. It has sometimes been considered important that
children in endemic areas have some exposure to malaria
parasites, to acquire immunity naturally, as otherwise they
might be more likely to experience severe disease in the
event of a future epidemic of malaria. Therefore, further
studies of the immunological and clinical consequences of
declining malaria endemicity are needed.
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Figure 5 (a) The decline and acquisition
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IgG3, IgG4, IgM and IgA, to MSP3-3D7
over the five time points 0, 4, 9, 18 and
36 months. Each line represents the
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Figure 6 (a) The decline and acquisition
of antibody isotypes IgG1, IgG2, IgG3,
IgG4, IgM and IgA to MSP2-ch150⁄9a t
the ages 0, 4, 9, 18 and 36 months. Each
line represents the measurement of anti-
body levels for an individual at different
ages. (b) The decline and acquisition of
the antibody isotypes, IgG1, IgG2, IgG3,
IgG4, IgM and IgA, to MSP2-Dd2 over
the five time points 0, 4, 9, 18 and 36
months. Each line represents the
measurement of antibody levels in an
individual at different ages.
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